Inhalation apparatus for generating sarin and soman toxic vapors. 2003

Lucie Sevelová, and Josef Vachek, and Jirí Bajgar
Purkyne Military Medical Academy, Hradec Králové: Department of Toxicology, Czech Republic. sevelova@pmfhk.cz

The developed inhalation system is a dynamic and whole-body exposure model designated for generating sarin or soman vapors. It consists of an evaporating apparatus, an inhalation chamber and a carbon filter. The inhalation chamber is made of stainless steel and its total volume is 36 l. The concentration of organophosphorus compound depends on airflow through the chamber, syringe volume of the dosing pump and dosing speed. For determination of organophosphorus compound (OPC) concentration, a modification of Ellman method is used. At generating of vapors in the inhalation chamber the means of the yield were 61.4 +/- 6.6% for sarin and 35.8 +/- 3.5% for soman. The better yield for sarin than for soman, because of the higher volatility of sarin in comparison with soman was achieved. The stable concentration of the OPC for several hours could be maintained in the inhalation chamber when only relatively small amount of the OPC is used. Using the developed inhalation system LCt50 for sarin and for soman in rats was determined. At 1 h exposure the LCt50 values were 4.72 mg x h(-1) x m(-3) for sarin and 4.81 mg x h(-1) x m(-3) for soman. The results presented show that the inhalation chamber successfully fulfils the role of instrument for inhalation intoxication of small laboratory animals with highly toxic OPC.

UI MeSH Term Description Entries
D002619 Chemical Warfare Agents Chemicals that are used to cause the disturbance, disease, or death of humans during WARFARE. Agents, Chemical Warfare,Warfare Agents, Chemical,Agent, Chemical Warfare,Chemical Warfare Agent,Warfare Agent, Chemical
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012524 Sarin An organophosphorus ester compound that produces potent and irreversible inhibition of cholinesterase. It is toxic to the nervous system and is a chemical warfare agent. Sarin Gas,o-Isopropylmethyl Phosphonofluoridate,ortho-Isopropylmethyl Phosphonofluoridate,Gas, Sarin,Phosphonofluoridate, o-Isopropylmethyl,Phosphonofluoridate, ortho-Isopropylmethyl,o Isopropylmethyl Phosphonofluoridate,ortho Isopropylmethyl Phosphonofluoridate
D012999 Soman An organophosphorus compound that inhibits cholinesterase. It causes seizures and has been used as a chemical warfare agent. Pinacolyl Methylphosphonofluoridate,Methylphosphonofluoridate, Pinacolyl
D014116 Toxicology The science concerned with the detection, chemical composition, and biological action of toxic substances or poisons and the treatment and prevention of toxic manifestations. Toxinology,Evidence Based Toxicology,Evidence-Based Toxicology,Based Toxicologies, Evidence,Based Toxicology, Evidence,Evidence Based Toxicologies,Evidence-Based Toxicologies,Toxicologies, Evidence Based,Toxicologies, Evidence-Based,Toxicology, Evidence Based,Toxicology, Evidence-Based

Related Publications

Lucie Sevelová, and Josef Vachek, and Jirí Bajgar
September 1985, Toxicology and applied pharmacology,
Lucie Sevelová, and Josef Vachek, and Jirí Bajgar
May 1990, Fundamental and applied toxicology : official journal of the Society of Toxicology,
Lucie Sevelová, and Josef Vachek, and Jirí Bajgar
March 1957, Zentralblatt fur Arbeitsmedizin und Arbeitsschutz,
Lucie Sevelová, and Josef Vachek, and Jirí Bajgar
May 1985, Biochemical pharmacology,
Lucie Sevelová, and Josef Vachek, and Jirí Bajgar
January 1982, European journal of nuclear medicine,
Lucie Sevelová, and Josef Vachek, and Jirí Bajgar
May 1987, Toxicology letters,
Lucie Sevelová, and Josef Vachek, and Jirí Bajgar
January 1965, Biochemical pharmacology,
Lucie Sevelová, and Josef Vachek, and Jirí Bajgar
June 2020, Journal of nanoscience and nanotechnology,
Lucie Sevelová, and Josef Vachek, and Jirí Bajgar
July 1988, Praxis und Klinik der Pneumologie,
Copied contents to your clipboard!